Pancreatic Ductal Adenocarcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 42 expanded access programs, clinical trials, and compassionate use pathways listed for Pancreatic Ductal Adenocarcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with pancreatic ductal adenocarcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 15 programs are currently active or recruiting, with the remaining 27 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), Phanes Therapeutics, Revolution Medicines, Inc., and others.
By recruiting status
Snapshot of where every Pancreatic Ductal Adenocarcinoma program currently sits in its lifecycle.
- Active / Recruiting15
- Inactive27
Top sponsors
Organisations running the most Pancreatic Ductal Adenocarcinoma programs in the directory.
- AstraZeneca3 programs
- Merck Sharp & Dohme LLC2 programs
- National Cancer Institute (NCI)2 programs
- Phanes Therapeutics2 programs
- Revolution Medicines, Inc.2 programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 programs
- Affini-T Therapeutics, Inc.1 program
- Alliance for Clinical Trials in Oncology1 program
- Baylor College of Medicine1 program
- Blue Earth Diagnostics1 program
Pancreatic Ductal Adenocarcinoma programs (42)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on [18F]FPyQCP PET Imaging for Detecting Certain Types of Cancer — Blue Earth Diagnostics
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- First Human Trial of BLU-924 for Advanced Cancers with KRAS Mutations — Blueprint Medicines Corporation
- Study on VS-7375 for Patients with KRAS G12D-Mutated Solid Tumors — Verastem, Inc.
- Phase 2 Study of Cediranib and Olaparib for Advanced Solid Tumors — National Cancer Institute (NCI)
- Study Comparing BMS-986504 with Nab-paclitaxel and Gemcitabine Versus Placebo for Untreated Metastatic Pancreatic Cancer with MTAP Deletion — Bristol-Myers Squibb
- Vaccine Study for Treating Gastrointestinal Cancers — Thomas Jefferson University
- Study on Atebimetinib and Modified Chemotherapy for First-Line Treatment of Metastatic Pancreatic Cancer — Immuneering Corporation
- Study on Mavrostobart (PT199) Alone and with Other Cancer Treatments (MORNINGSTAR Study) — Phanes Therapeutics
- Study on Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy for Advanced Pancreatic Cancer — The University of Texas Health Science Center, Houston
- Study on iExosomes for Treating Metastatic Pancreatic Cancer with KrasG12D Mutation — M.D. Anderson Cancer Center
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Study on AZD4360 for Adults with Advanced Solid Tumors — AstraZeneca
- Study on Elironrasib and Daraxonrasib for Advanced KRAS G12C Mutant Solid Tumors — Revolution Medicines, Inc.
- Study on ZN-c3 and Gemcitabine for Pancreatic Cancer — Brandon Huffman
- Study on MK-2870 Alone or With Chemotherapy for Treating Gastrointestinal Cancers — Merck Sharp & Dohme LLC
- Study on ELI-002 7P for Patients with KRAS/NRAS Mutated Solid Tumors — Elicio Therapeutics
- Study on NALIRIFOX and Radiation Therapy for Pancreatic Cancer — Memorial Sloan Kettering Cancer Center
- Study of OT-101 with mFOLFIRINOX for Advanced Pancreatic Cancer — Oncotelic Inc.
- Study on IPN01194 for Adults with Advanced Solid Tumors — Ipsen
- Study on the Effects of CT3001 in Patients with Advanced Solid Tumors — Crossignal Therapeutics, Inc.
- Study on AGEN1423 and Botensilimab with or without Chemotherapy for Advanced Pancreatic Cancer — Bruno Bockorny
- Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer — Georgetown University
- Study on AZD0901 for Patients with Advanced Solid Tumors Expressing Claudin18.2 — AstraZeneca
- Combination Therapy for Patients with Localized Pancreatic Cancer — Gulam Manji
- Study on Enfortumab Vedotin for Previously Treated Advanced Pancreatic Cancer (EPIC) — University of Kansas Medical Center
- Study on Hepatic Artery Chemotherapy for Patients with Localized Pancreatic Cancer — Duke University
- Study on Continuous Infusion of LSTA1 with Standard Treatment for Metastatic Pancreatic Cancer — Lisata Therapeutics, Inc.
- Study on Chemotherapy and Immunotherapy Before Surgery for Patients with Resectable Pancreatic Cancer — Baylor College of Medicine
- Study on Personalized Chemotherapy for Metastatic Pancreatic Cancer — University Health Network, Toronto
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) — Merck Sharp & Dohme LLC
- Phase I Study of Personalized T Cell Therapy for Advanced or Metastatic Solid Tumors with KRAS G12V Mutation — Affini-T Therapeutics, Inc.
- Study on PT886 for Treating Advanced Stomach, Gastroesophageal, and Pancreatic Cancers (TWINPEAK Study) — Phanes Therapeutics
- Study on AZD5863 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway — Deciphera Pharmaceuticals, LLC
- Study on Nab-Paclitaxel and Gemcitabine With or Without SBP-101 for Pancreatic Cancer — Panbela Therapeutics, Inc.
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on Pembrolizumab With or Without Defactinib Before and After Surgery for Treating Resectable Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on RAS(ON) Inhibitors for Patients with Gastrointestinal Solid Tumors — Revolution Medicines, Inc.
- Tegavivint for Treating Recurrent or Hard-to-Treat Solid Tumors, Including Lymphomas and Desmoid Tumors — Children's Oncology Group
- The PLATINUM Trial: Optimizing Chemotherapy for Second-Line Treatment of Metastatic Pancreatic Cancer with BRCA1/2 or PALB2 Mutations — Alliance for Clinical Trials in Oncology
- Trial of Nivolumab and BMS-813160 with or without GVAX for Locally Advanced Pancreatic Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Pancreatic Ductal Adenocarcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.